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Structured Abstract 
Context: Excess visceral fat is associated with chronic systemic inflammation 
and cardiovascular complications. Pioglitazone has been reported to variably 
influence visceral fat volume, but its effect on metabolic activity of the visceral fat 
remains uncharacterized.  
Objective: The aim of this study was to assess the effects of pioglitazone on 
glucose metabolism of fat tissue by using 18F-fluorodeoxyglucose 
(FDG)-positron emission tomography (PET) and computed tomography (CT) 
imaging. 
Design, Setting, and Participants: FDG-PET and computed tomography 
imaging were performed in 56 patients with impaired glucose tolerance (IGT) or 
type 2 diabetes mellitus (T2DM); lipid and glycemic profiles and inflammatory 
biomarkers were obtained in all patients. These patients were randomized to 
treatment with either pioglitazone or glimepiride for 16 weeks. 
Main Outcome Measures: The metabolic activity of the visceral fat tissues as 
assessed by FDG uptake was expressed as a target-to-background ratio (TBR) 
of blood-normalized standardized uptake value.  
Results: The study was completed in 32 pioglitazone-treated and 21 
glimepiride-treated patients (40 males and 13 females; mean age, 67.78.1 
years; body mass index, 25.03.6 kg/m2; HbA1c, 6.780.70 %). Both treatments 
were well-tolerated and comparably improved glycemic control. At baseline, 
visceral fat exhibited a higher TBR value than subcutaneous fat (0.55±0.14 vs 
0.30±0.07, P<0.001). Pioglitazone significantly decreased the visceral fat 
volume (130.5±53.0 to 122.1±51.0 cm2, P=0.013) and TBR values (0.57±0.16 to 
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0.50±0.11, P=0.007); glimepiride did not influence visceral fat volume or TBR 
values. Neither pioglitazone nor glimepiride treatment showed any effect on the 
volume or TBR values of subcutaneous fat. After 16-week treatment with 
pioglitazone reduction in visceral fat TBR was correlated to increase in HDL 
cholesterol levels.  
Conclusions: Our study indicated that pioglitazone decreased the visceral fat 
volume and its metabolic activity in patients with IGT or T2DM. The beneficial 
effects of pioglitazone on visceral fat may be independent of its glucose-lowering 
effect. 
 
 
Abbreviations: IGT, impaired glucose tolerance; T2DM, type 2 diabetes 
mellitus; CT, computed tomography; FDG, 18F-fluorodeoxyglucose; PET, 
positron emission tomography; PPAR, peroxisome proliferator-activated 
receptor; FPG, fasting plasma glucose; BMI, body mass index; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin; hsCRP, 
high-sensitivity C-reactive protein; ROI, region of interest; SUV, standardized 
uptake value; TBR, target-to-background ratio.
 - 4 - 
Obesity has reached epidemic proportions globally and has become a major 
public health concern (1-3). The visceral obesity is closely associated with 
chronic inflammation and disturbed adipocytokine profiles, and consequently 
contributes to the risk of a variety of metabolic disorders including hypertension, 
dyslipidemia, insulin resistance, and hyperglycemia (4,5). The visceral obesity is 
considered a major risk factor for impaired glucose tolerance (IGT), type 2 
diabetes mellitus (T2DM) and cardiovascular disease (6-8).  
Fat tissue volume has been traditionally measured by computed tomography 
(CT) imaging (9,10), and combined imaging with 18F-fluorodeoxyglucose 
(FDG)-positron emission tomography (PET) allows simultaneous assessment of 
the metabolic activity of adipose tissue (11). An increased visceral fat volume is 
associated with both hyperplasia and hypertrophy of adipocytes, expression of 
inflammatory biomarkers (4,12), and higher metabolic rates and oxygen 
consumption. Visceral fat tissues have demonstrated a higher FDG-verified 
metabolic activity compared with subcutaneous fat tissues (11). 
Pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-gamma 
agonist, is a commonly used oral hypoglycemic agent for the treatment of T2DM 
(13). It improves insulin resistance and ameliorates hyperglycemia in diabetes; 
pioglitazone also demonstrates an anti-oxidative and anti-inflammatory property, 
considered a pleiotropic action in humans (14-16). Since PPAR-gamma is a key 
transcriptional factor that induces the differentiation from a pre-adipocyte to 
matured adipocyte and stimulates the induction of enzymes involved in 
lipogenesis (17-19), it is possible that pioglitazone may increase subcutaneous 
fat volume (20-22). There still remains a controversy about the effects of 
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pioglitazone on visceral fat volume (20-23) and metabolic activity. In this study, 
using FDG-PET and CT imaging, we examined the effects of pioglitazone on 
volume and metabolic activity of visceral and subcutaneous fat tissues of 
patients with IGT or T2DM. The influence of pioglitazone was compared with that 
of glimepiride, another oral hypoglycemic agent. 
 
Subjects and Methods 
Study design and patients 
This present study comprised a 16-week prospective, randomized, open-label, 
comparator-controlled, single-center intervention design. IGT was diagnosed by 
75 gram oral glucose tolerance test and T2DM was defined as recommended by 
the current diagnostic criteria of the American Diabetes Association (24). Fifty 
eight patients with IGT or T2DM who underwent whole-body PET and CT scan 
were prospectively enrolled for evaluation fat volume and FDG activity in the 
abdominal fat tissues. We excluded any patients with uncontrolled diabetes 
(fasting plasma glucose [FPG] 200 mg/dL), treatment regimen including 
pioglitazone or insulin, significant hepatic disorders (aminotransferase 2.5-fold 
the specific normal value), left ventricular dysfunction (left ventricular ejection 
fraction 40%) or heart failure (New York Heart Association functional class II), 
symptomatic coronary artery disease or symptomatic stroke within past 6 
months at enrollment, vasculitis, collagen disease, pneumonia, or malignancy. 
All patients were enrolled after their first screening visit; two patients met the 
exclusion criteria. Of 56 patients, 34 were allocated to pioglitazone arm and 22 
to glimepiride arm. We could not obtain the informed consent from some patients 
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assigned to glimepiride group. This is a reason why there was a 1.5:1 ratio 
between the 2 groups. All study measurements were obtained at study entry and 
at the end of the observation period after 16 weeks. The disposition of patients in 
the study is shown in Figure 1. Two patients from pioglitazone arm and 1 from 
glimepiride arm withdrew before the follow-up evaluation at 16 weeks. Written 
informed consent was obtained from all patients. The research protocol was 
reviewed and approved by the Ethical Committee for Clinical Research of 
Kurume University approved this study. The trial was duly registered with Clinical 
Trial Registration (NCT00722631). 
 
Pharmacological treatment 
The consecutive eligible patients who had never received pioglitazone were 
randomized to receive either pioglitazone 15 mg daily in the morning or 
glimepiride 0.5 to 1 mg daily, as an active comparator. In the glimepiride group, 
when FPG level was 150 mg/dL, we chose the starting dose of 1 mg 
glimepiride. If patients were already being treated for hyperglycemia and were 
not optimally controlled, glimepiride or pioglitazone was added. Pioglitazone or 
glimepiride dose was titrated for optimal glycemic control for 16 weeks. The 
optimal glycemic control was defined as FPG level of 110 mg/dL. Any 
medications for hypertension, diabetes, dyslipidemia, or antiplatelet remained 
unchanged during the course of the study period.  
 
Data collection 
Presence of smoking habit, medical history, use of medication, and family history 
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of cardiovascular disease were assessed by a questionnaire. Smoking status 
was classified as current smoking or not smoking. Weight and height were 
measured to calculate body mass index (BMI). Waist circumference was 
measured at the umbilical level in the late exhalation phase. BMI and waist 
circumference were measured as an index of obesity. Blood pressure was 
measured in the sitting position using an upright standard sphygmomanometer. 
Vigorous physical activity and smoking were avoided for at least 30 minutes 
before resting blood pressure and heart rate measurements. 
 At baseline and 16 weeks after the treatments, blood was obtained from all 
the patients in the morning after an overnight fast of more than 12 hours for 
determinations of lipid profiles {low-density lipoprotein (LDL) cholesterol, 
triglycerides, and high-density lipoprotein (HDL) cholesterol}, FPG and serum 
immunoreactive insulin, glycated hemoglobin (HbA1c), estimated glomerular 
filtration rate, high-sensitivity C-reactive protein (hsCRP), and total adiponectin. 
These blood chemistry variables were measured by standard methods at a 
commercial laboratory (The Kyodo Igaku Laboratory, Fukuoka, Japan) as 
described previously (25). The value for HbA1c (%) is estimated as a National 
Glycohemoglobin Standardization Program equivalent value (%) calculated by 
the formula HbA1c (National Glycohemoglobin Standardization Program) (%) = 
1.02  HbA1c (Japan Diabetes Society) (%) + 0.25% (26). 
 
Adipose tissue imaging 
Adipose tissue imaging was performed by a hybrid PET-CT after at least 12-hour 
of fasting. In brief, the enrollees received an intravenous administration of FDG 
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(4.2 MBq [0.12 mCi]/kg body weight) through the antecubital vein. One hour after 
the FDG injection, 3-dimensional whole-body PET imaging was carried out using 
an integrated full-ring PET and 16-slice multidetector computed tomography 
(CT) scanner (Gemini-GXL 16, Philips Medical Systems, Inc., Cleveland, Ohio). 
The non-contrast CT data were used for attenuation correction and localization. 
After both the transmission and emission images were obtained, images were 
reconstructed using the 3-dimensional line-of-response row-action maximum 
likelihood algorithm (3D-LOR-RAMLA, Philips, Eindhoven, the Netherlands).  
 
Abdominal fat distribution 
Abdominal fat distribution was estimated by calculating subcutaneous and 
visceral fat areas using a standardized method with CT scan and Fat Scan 
software (N2 System Corp, Osaka, Japan) (9) (Figure 2A). In brief, a region of 
interest (ROI) of the fat layer was defined by tracing its contour on each scan, 
and the attenuation range of CT numbers in Hounsfield units for fat tissue was 
calculated. The fat area was determined as the average of areas at the umbilical 
level and the additional 10 levels separated by 4 mm in length in top and bottom 
from the umbilical level obtained from consecutive CT images (Figure 2B). The 
investigators who performed the measurements of fat tissue were blinded to the 
patients’ characteristics. 
 
Metabolic activity in the fat tissues 
Metabolic activity in the fat tissues was assessed by FDG-PET and CT scan. 
National Institutes of Health ImageJ was used for image analysis. We created a 
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“fat mask image” from the original CT image and a “re-sampled PET image” from 
the original PET image set by corresponding to fat volume slices in the patients, 
and then combined them to accomplish a “PET fat mask image” on a workstation 
as described previously (11) (Figure 2C). We drew ROIs in each contour of 
visceral and subcutaneous fat tissues in consecutive levels and evaluated as 
follows. The intensity of FDG uptake was quantified by measuring the 
standardized uptake value (SUV) corrected for body weight, injected FDG dose, 
and ROI volume. Subsequently, the FDG uptake on the fat tissue was corrected 
for blood activity by dividing by venous blood SUV to produce a blood-corrected 
glucose metabolism; as known target-to-background ratio (TBR). We then 
averaged TBR values from 11 levels to obtain a TBR score in both 
subcutaneous and visceral fat tissue regions. Two blinded radiologists 
measured the volume and FDG uptake on the fat tissues. The intraobserver or 
interobserver variability of these measurements was less than 5%. 
 
Statistical analysis  
Data were analyzed by with per protocol results rather than intention-to-treat. 
Data were described presented as mean values ± standard deviation or medians 
with the interquartile range. We performed the Shapiro-Wilk test to evaluate the 
assumption of normality. Statistical analysis was performed by means of 
appropriate parametric and nonparametric methods. Treatment groups were 
compared at baseline by using an unpaired t-test for continuous variables and 2 
for categorical variables. First, 2-tailed paired t-test was performed for 
comparisons between the baseline and post-treatment. Second, the changes 
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from baseline were compared by 2-tailed unpaired t-test between the two groups. 
Statistical significance was defined as P < 0.05. All statistical analyses were 
performed with the use of the SPSS system (SPSS Inc., Chicago, IL).  
 
Results 
Study design  
Of 58 enrolled patients, 2 patients were excluded due to cancer diagnosis before 
the randomization. Finally, 56 patients were randomly assigned to receive either 
pioglitazone (N=34) or glimepiride (N=22). But, 3 patients dropped out of the 
study because of refusal of assessment of blood chemistry or drug treatment. 
The study was completed by 53 patients (Figure 1). A summary of the baseline 
characteristics of the patients in each group are presented in Table 1. As shown 
in Table 1, baseline characteristics were well-matched between the two groups 
with respect to gender distribution, age, BMI, waist circumference, blood 
pressure, renal function, lipids, glycemic or inflammatory status, and plasma 
adiponectin concentrations at baseline. Percentage of patients who were taking 
medications for diabetes or hypertension, statins or aspirin was similar between 
the two groups, and doses of these drugs were not changed during the 
intervention periods.  
 
Effects of pioglitazone and glimepiride 
Both treatments were well-tolerated. The average daily dose of glimepiride was 
1.3  1.1 mg daily, and that of pioglitazone 16.4  4.3 mg daily. No 
treatments-related adverse side effects such as hospitalization for heart failure 
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or severe hypoglycemia were observed in the present study. Table 2 shows the 
clinical variables in both treatment groups at the baseline and end of the study. 
Glycemic control evaluated by FPG or HbA1c was similar between the two 
groups. Fasting insulin concentrations remained unchanged in the both groups. 
There were no significant changes of blood pressure, LDL cholesterol or 
triglycerides during the study periods in either group. HDL cholesterol was 
significantly increased in the pioglitazone group (P = 0.002), but not in the 
glimepiride group (P = 0.150). Pioglitazone significantly decreased serum level 
of hsCRP (P < 0.001), whereas it significantly increased in glimepiride group (P 
= 0.018). Also, treatment with pioglitazone was associated with significant 
increase in plasma adiponectin concentrations (P < 0.001), but glimepiride did 
not affect the adiponectin level (P = 0.366). 
 
Treatment effect on visceral fat volume 
Although there was no significant difference in change of waist circumference 
from baseline between the two groups, pioglitazone (P = 0.016), but not 
glimepiride (P = 0.469), modestly increased waist circumference, whereas either 
treatment did not affect body weight. In the pioglitazone group, the change in 
waist circumference was inversely associated with that in glycemic control (FPG, 
r = -0.46, P = 0.008; HbA1c, r = -0.47, P = 0.006), but not that in visceral fat (r = 
-0.25, P = 0.168) or subcutaneous fat volume (r = -0.04, P = 0.815). There was 
no significant change in subcutaneous fat volume after either treatment (Table 3). 
However, a significant decrease in visceral fat volume was only observed by the 
treatment with pioglitazone (P = 0.013; Table 3). Representative cases after both 
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treatments are shown in Figure 3. The decrease in the visceral fat volume was 
correlated with the increase in plasma adiponectin concentration using both 
groups, but not pioglitazone group only (r = -0.20, P = 0.298 in the pioglitazone 
group; r = -0.30).  
 
Treatment effect on metabolic activity of adipose tissues 
There was no significant difference of TBR values in the subcutaneous or 
visceral fat between the two groups at baseline. The visceral fat tissues 
exhibited a substantially higher metabolic activity than subcutaneous fat tissues 
(P < 0.001); the result was consistent with that of the previous report (11). For 
the visceral fat tissues, pioglitazone significantly decreased the metabolic 
activity (P = 0.007), but glimepiride did not (P = 0.145; Table 3). Either treatment 
did not affect the metabolic activity in the subcutaneous fat tissues (Table 3). 
Although pioglitazone significantly decreased the visceral fat volume, there was 
no significant association between reduction of visceral fat volume and 
suppression of its metabolic activity (r = -0.01, P = 0.958). The decrease in 
metabolic activity in the visceral fat tissues was significantly associated with the 
elevation of HDL cholesterol (r = -0.59, P < 0.001 in the pioglitazone group; r = 
-0.153; P = 0.508 in the glimepiride group), but not with the changes in waist 
circumference, FPG, HbA1c, or adiponectin concentrations.  
 
Discussion 
It is well established that visceral adiposity is associated with insulin resistance 
and that thiazolidinediones improve diabetes control by lowering insulin 
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resistance (27). Therefore, it is conceivable that pioglitazone may decrease 
visceral fat volume with the mechanism by which it improves diabetic control. 
However, numerous clinical studies have yielded inconsistent results about the 
effects of pioglitazone on abdominal fat volume (20-23). Further, the relationship 
between visceral fat volume and its metabolic activity is unclear, and effects of 
pioglitazone on metabolic activity of adipose tissues are largely unknown. 
Therefore, in this study, we compared the effects of pioglitazone and glimepiride 
on visceral fat volume and its metabolic activity in patients with IGT or T2DM. 
The treatment with pioglitazone for 16 weeks, but not glimepiride substantially 
reduced the visceral fat volume and its metabolic activity. On the other hand, 
neither treatment affected the subcutaneous fat volume or activity. Since there 
was no significant difference in glycemic control and lipid profile between the two 
treatment groups, the beneficial effects of pioglitazone on visceral adipose 
tissues may be independent on its glucose-lowering property or possibly its 
pleiotropic action.  
Visceral adipocytes are recognized as an endocrine organ, which 
produce various pro-inflammatory cytokines such as tumor necrosis factor-alpha 
(28-30). In addition, recently, cytokine-induced macrophage infiltration into the 
adipose tissues has been shown to further augment the inflammatory milieu (31). 
Therefore, visceral adiposity and enhanced inflammatory reactions could induce 
a vicious cycle to exaggerate insulin resistance and augment the risk of 
cardiovascular disease (32,33). In the study, we found that pioglitazone 
significantly decreased the metabolic activity in the visceral fat tissues, which 
inversely correlated with increase in HDL cholesterol levels. Lack of any 
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relationship between the decrease in visceral fat and decrease in its metabolic 
activity in the pioglitazone group has suggested that visceral fat volume and its 
metabolic activity may be differently regulated. 
Waist circumference in the pioglitazone group is slightly increased even 
though pioglitazone treatment decreased visceral fat volume without any 
significant changes in subcutaneous fat. So, waist circumference may not 
necessarily reflect changes in visceral adiposity. In this study, reduction of 
metabolic activity in the visceral fat tissues was significantly associated with the 
elevation of HDL cholesterol in the pioglitazone group, whereas decrease in 
visceral fat volume was significantly correlated with the increase in plasma 
adiponectin concentration using both groups only. The lack of association in the 
pioglitazone group is probably related to the small number of study group. 
We, along with others, have found that FDG-PET is a reliable and 
sensitive method for quantifying vascular inflammation and identifying vulnerable 
plaques within an area of atherosclerosis (34,35). Further, we have shown that 
vascular FDG uptake activity is significantly higher in proportion to the 
accumulation to the number of the components of the metabolic syndrome and 
negatively correlated with HDL-cholesterol levels (35). Our present findings 
suggest that pioglitazone could have insulin-sensitizing and anti-atherogenic 
properties in humans partly via its anti-inflammatory actions on visceral adipose 
tissues. In this study, although pioglitazone treatment significantly decreased the 
visceral fat volume, there was no association between the reduction of fat 
volume and suppression of the metabolic activity in adipose tissues. Moreover, 
the change in the visceral fat volume after treatments was inversely correlated 
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with that in plasma adiponectin concentrations. Size of fat cells in adipose 
tissues is associated with insulin sensitivity; adipocyte size is positively 
correlated with pro-inflammatory adipocytokines levels, while inversely 
associated with adiponectin levels (36). Pioglitazone has been reported to 
induce differentiation of pre-adipocytes into adipocytes, thereby increasing the 
number of small adipocytes because of both the appearance of the new 
adipocytes and the shrinkage and/or disappearance of existing mature 
adipocytes (37,38). Therefore, there could exist two distinct insulin-sensitizing 
mechanisms for piogitazone in visceral fat tissues including the reduction of fat 
cell size (possibly associated with the elevation of adiponectin), and the 
suppression of inflammatory reactions (possibly linked to increase in HDL 
cholesterol levels).  
 
Study Limitation 
The small sample size may limit the findings of the present study. We can not 
confirm that FDG uptake represents a true reduction in inflammatory activity in 
adipose tissue due to our inability in obtaining the fat tissue biopsy. It is also not 
known as to which type of cells would reflect the FDG uptake in adipose tissues. 
Although the primary endpoints failed to reach statistical significance in the 
PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) 
study, pioglitazone significantly reduced the composite of all-cause mortality, 
non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who 
have a high risk of macrovascular events (15). Furthermore, in a subgroup 
analysis from PROactive, pioglitazone significantly reduced the risk of recurrent 
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stroke and myocardial infarction in high-risk patients with type 2 diabetes (39,40). 
Longitudinal study is needed to examine whether unique and glucose-lowering 
independent effects of pioglitazone on visceral adipose tissues could indeed 
contribute to the risk reduction of cardiovascular disease.  
In conclusion, we observed that pioglitazone treatment may lead to 
decrease visceral fat volume and its metabolic activity in IGT or T2DM patients. 
Its glycemic control independent effect on visceral adipose tissues may partly 
explain the beneficial effect of pioglitazone on cardiometabolic disorders.  
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Figure legends 
Figure 1. Disposition of patients. 
Eligible 56 patients were randomly assigned to receive either pioglitazone or 
glimepiride as an active comparator for 16 weeks. The study was fully completed 
by 32 patients in the pioglitazone group and 21 in the glimepiride group.  
IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus; FDG-PET, 
18F-fluorodeoxyglucose-positron emission tomography; CT, computed 
tomography. 
 
Figure 2. Analyses of abdominal fat distribution. 
Abdominal fat distribution was estimated using CT imaging and Fat Scan 
software. Magenta area indicates subcutaneous fat, while red area shows 
visceral fat (A). The fat area was determined as the average of areas at the 
umbilical level and the additional 10 levels separated by 4 mm in length in top 
and bottom from the umbilical level obtained from consecutive CT images (B). 
We created a “fat mask image” from the original CT image and a “re-sampled 
PET image” from the original PET image set by corresponding to fat volume 
slices in the patients, and then combined them to accomplish a “PET fat mask 
image” on a workstation (C). 
 
Figure 3. Treatment effects on abdominal fat volume. 
Representative computed tomography at baseline (left) and after 16-week 
treatment (right) with pioglitazone (top) or glimepiride (bottom). Note the 
reduction in fat volume in the visceral fat tissues by pioglitazone treatment. 
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Table caption 
Table 1. Patient characteristics. 
LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; CRP, 
C-reactive protein. 
Values are n (%), mean  SD, or *median (interquartile range). 
Table 2. Clinical data at baseline and after 16-week treatment with 
pioglitazone or glimepiride.  
Values are mean  SD or *median (interquartile range). 
Table 3. Changes in adipose tissue parameters after 16-week treatment 
with pioglitazone or glimepiride.  



Parameters Pioglitazone (n=32) Glimepiride (n=21) P value
Male, n (%)   23 (71.9) 17 (81.0) 0.671
Age (years) 68.4 (7.3) 66.7 (9.1) 0.460
Body mass index (kg/m2) 25.2 (3.5) 24.7 (3.7) 0.594
Waist circumference (cm) 89.6 (10.0) 89.1 (10.8) 0.844
Systolic blood pressure (mmHg) 129.9 (12.2) 123.1 (13.5) 0.068
Diastolic blood pressure (mmHg) 70.7 (9.1) 69.1 (9.5) 0.553
LDL cholesterol (mg/dL) 109.8 (25.8) 116.2 (24.5) 0.381
HDL cholesterol (mg/dL) 48.4 (12.2) 51.5 (13.2) 0.388
Triglycerides* (mg/dL)    113.0 [86.0-159.8]   121.0 [78.8-165.0]  0.682
Estimated GFR (mL/min) 68.2 (15.6) 69.1 (17.9) 0.851
Fasting plasma glucose* (mg/dL)   122.5 [110.0-146.3]   131.0 [121.0-146.0] 0.555
Fasting plasma insulin* (µU/mL)  7.15 [5.03-11.35] 4.70 [3.55-8.50] 0.100
Hemoglobin A1c (%) 6.72 (0.72) 6.87 (0.64) 0.454
High-sensitivity CRP* (mg/dL)      0.74 [0.33-1.94] 0.51 [0.34-1.51] 0.994
Adiponectin* (µg/mL) 4.56 [2.32-6.33] 5.01 [2.64-7.67] 0.855
Current smoking, n(%) 5 (15.6) 4 (19.0) 0.961
Coronary artery disease, n(%) 17 (53.1) 12 (57.1) 0.774
Cerebral vascular disease, n(%) 4 (12.5) 6 (28.6) 0.270
Medications, n(%)                          
          For diabetes 13 (40.6) 12 (57.1) 0.234
          For hypertension 30 (93.8) 17 (81.0) 0.320
          Statins 18 (56.3) 9 (42.9) 0.340
          Aspirin 17 (53.1) 15 (71.4) 0.183
Systolic blood pressure (mmHg)
          Baseline 129.9 (12.2) 123.1 (13.5) 0.068
          Post treatment 126.7 (14.6) 124.0 (14.4) 0.519
          P value vs baseline 0.136 0.733
Diastolic blood pressure (mmHg)
          Baseline 70.7 (9.1) 69.1 (9.5) 0.553
          Post treatment 71.6 (9.7) 68.3 (10.0) 0.245
          P value vs baseline 0.623 0.459
LDL cholesterol (mg/dL) 
          Baseline 109.8 (25.8) 116.2 (24.5) 0.381
          Post treatment 109.6 (26.2) 117.8 (20.2) 0.236
          P value vs baseline 0.952 0.705
HDL cholesterol (mg/dL) 
          Baseline 48.4 (12.2) 51.5 (13.2) 0.388
          Post treatment 53.8 (14.1) 53.7 (12.6) 0.972
          P value vs baseline 0.002 0.150
Triglycerides* (mg/dL) 
          Baseline 113.0 [86.0-159.8] 121.0 [78.0-165.0] 0.682
          Post treatment 119.5 [82.3-149.8] 123.0 [83.0-208.5] 0.785
          P value vs baseline 0.787 0.186
Fasting plasma glucose* (mg/dL)
          Baseline 122.5 [110.0-146.3] 131.0 [121.0-146.0] 0.555
          Post treatment 114.5 [102.8-123.3] 119.0 [111.5-131.0] 0.375
          P value vs baseline 0.003 <0.001
Fasting plasma insulin* (µU/mL) 
          Baseline 7.15 [5.03-11.35] 4.70 [3.55-8.50] 0.100
          Post treatment 6.55 [4.20-9.68] 5.50 [3.80-7.25] 0.519
          P value vs baseline 0.057 0.808
Hemoglobin A1c (%) 
          Baseline 6.72 (0.72) 6.87 (0.64) 0.454
          Post treatment 6.36 (0.77) 6.50 (0.52) 0.462
          P value vs baseline 0.004 <0.001
High-sensitivity CRP* (mg/L) 
          Baseline 0.74 [0.33-1.94] 0.51 [0.34-1.51] 0.306
          Post treatment 0.50 [0.27-0.94] 1.04 [0.44-2.10] 0.010
          P value vs baseline <0.001 0.018
Adiponectin* (µg/mL) 
          Baseline 4.56 [2.32-6.33] 5.01 [2.64-7.67] 0.855
          Post treatment 11.33 [6.20-19.32] 5.63 [2.76-8.41] 0.002
          P value vs baseline <0.001 0.366
Parameters Pioglitazone Glimepiride
P value
between groups
Weight (kg) 
          Baseline 65.5 (12.3) 65.6 (11.0) 0.976
          Post treatment 66.1 (12.4) 66.1 (10.6) 0.989
          P value vs baseline 0.126 0.153
Waist circumference (cm)
          Baseline 89.6 (10.0) 89.1 (10.8) 0.844
          Post treatment 90.9 (9.5) 89.5 (10.2) 0.603
          P value vs baseline 0.016 0.469
Subcutaneous fat volume (cm2)
          Baseline 141.7 (49.1) 139.9 (59.9) 0.910
          Post treatment 146.5 (49.6) 134.5 (52.0) 0.411
          P value vs baseline 0.318 0.301
Visceral fat volume (cm2)
          Baseline 130.5 (53.0) 119.8 (54.0) 0.486
          Post treatment 122.1 (51.0) 122.5 (51.7) 0.978
          P value vs baseline 0.013 0.506
Subcutaneous fat activity
          Baseline 0.30 (0.07) 0.30 (0.06) 0.951
          Post treatment 0.29 (0.06) 0.32 (0.06) 0.085
          P value vs baseline 0.326 0.119
Visceral fat activity
          Baseline 0.57 (0.16) 0.54 (0.11) 0.455
          Post treatment 0.50 (0.11) 0.58 (0.09) 0.015
          P value vs baseline 0.007 0.145
P value
between groupsParameters Pioglitazone Glimepiride
